Journal Report

LEUKEMIA

Download PDF
Journal Information
Journal Title
LEUKEMIA
Publisher
SPRINGERNATURE
ISSN
0887-6924
E-ISSN
1476-5551
Database
Clarivate
Domain
Health Sciences, Life Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Hyperactivation of type I IFN signaling underlies a broad inflammatory program in VEXAS syndrome
Sandra G. Obwar, Dilshad H. Khan, Adriana Chiaramida et al.
2026-11-5
DOI: 10.1038/s41375-026-03186-9
Maternal donor risk in haploidentical transplant with post-transplant cyclophosphamide: the role of recipient sex
Rachel E. Granberg, Feng Gao, Melissa Mavers et al.
2026-11-5
DOI: 10.1038/s41375-026-03179-8
Mutant calreticulin-driven myeloproliferative neoplasms favour the emergence of TIGIT-positive NK cells
Agnieszka Witalisz-Siepracka, Theresa Harm, Thorsten Klampfl et al.
2026-11-3
DOI: 10.1038/s41375-026-03175-y
Salvage therapy for immune-mediated bone marrow failure
Serhan Unlu, Aashray Mandala, Mark D. Orland et al.
2026-11-3
DOI: 10.1038/s41375-026-03180-1
Relcobatinib, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia
Stefan D. Gross, Christopher A. Eide, Michael R. Burkard et al.
2026-11-3
DOI: 10.1038/s41375-026-03184-x
The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma
Olivia B. Farag, Bassel Awada, Abdessamad A. Youssfi et al.
2026-11-2
DOI: 10.1038/s41375-026-03174-z
Clinical and molecular characteristics of FLT3-ITD microclones in elderly patients with acute myeloid leukemia receiving less-intensive therapy
Henri C. Hupe, Rintaro Kubo, Razif Gabdoulline et al.
2026-10-30
DOI: 10.1038/s41375-026-03165-0
Rapid proteasomal degradation of mutant feline McDonough sarcoma-like tyrosine kinase-3 overcomes inhibitor resistance mechanisms of acute myeloid leukemia cells
Melisa Halilovic, Mohamed Abdelsalam, Andreas O. Mieland et al.
2026-10-28
DOI: 10.1038/s41375-026-03168-x
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies
Yun Wang, Chunhua Li, Robert Peter Gale et al.
2026-10-28
DOI: 10.1038/s41375-026-03185-w
Serine auxotrophy is a targetable vulnerability driven by PSAT1 suppression in AML
Ilias Sinanidis, Panagiotis Tsakiroglou, Benjamin Dubner et al.
2026-10-23
DOI: 10.1038/s41375-026-03176-x
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: November 9, 2026 05:35